Wider Use of CGM May Benefit People With Type 2 Diabetes
Continuous glucose monitoring (CGM) can benefit a much broader group of patients with type 2 diabetes than those for whom it is currently recommended, and who have access to it, new research suggests. The data come from two studies, both published online June 2 in JAMA. One study, a randomized clinical trial, showed that CGM use resulted in significantly improved A1c at 8 months among adults with type 2 diabetes taking long-acting insulin alone without premeal insulin. The study will also be presented during the virtual 14th International Conference on Advanced Technologies & Treatments for Diabetes.
@poulami These data expand "the number of people who could benefit from these devices, and points to a possible future in which CGMs are common in primary care clinics across the US." The other data come from a retrospective cohort study in a large California healthcare delivery system of insulin-treated patients with type 1 or type 2 diabetes selected by their primary care physicians for real-time CGM. Those with type 2 diabetes experienced a greater reduction in A1c than those with type 1 diabetes who initiated CGM.